- Conditions
- Alzheimer Disease, Caregivers
- Interventions
- Psychosocial information, counseling, and support, Donepezil (Aricept)
- Behavioral · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 151
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer's Disease
- Interventions
- Placebo, RO5313534
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 15
- States / cities
- Orange, California • Torrance, California • Norwalk, Connecticut + 11 more
- Conditions
- Healthy Volunteers
- Interventions
- Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Donepezil HCI (drug)
- Drug
- Lead sponsor
- Neurognostics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Alzheimer's Disease
- Interventions
- Donepezil
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 45 Years to 91 Years
- Enrollment
- 915 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Santa Ana, California
- Conditions
- Alzheimer's Disease
- Interventions
- Placebo, ABT-126, donepezil
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Fresno, California • West Palm Beach, Florida • Indianapolis, Indiana
- Conditions
- Healthy
- Interventions
- Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alzheimer Disease, Healthy Aging
- Interventions
- Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease
- Device
- Lead sponsor
- Bright Cloud International Corp
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- North Brunswick, New Jersey
- Conditions
- Alzheimer's Disease, Central Nervous System Diseases
- Interventions
- EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Comparator: Placebo, Donepezil, Rivastigmine
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- San Diego, California • Hallandale, Florida • Berlin, New Jersey + 1 more
- Conditions
- Healthy
- Interventions
- Donepezil
- Drug
- Lead sponsor
- Ranbaxy Laboratories Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Depression, Dementia
- Interventions
- Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Smoking
- Interventions
- Donepezil, Placebo
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Parkinson Disease
- Interventions
- Donepezil, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Alzheimer's Disease, Dementia
- Interventions
- Placebo, donepezil (Aricept)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alzheimer Disease, Healthy Aging
- Interventions
- BrightGo cognitive training, Standard of Care medication for early Alzheimer's Disease
- Device · Drug
- Lead sponsor
- Bright Cloud International Corp
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • North Brunswick, New Jersey
- Conditions
- Alzheimer's Disease
- Interventions
- dimebon
- Drug
- Lead sponsor
- Medivation, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Sun City, Arizona
- Conditions
- Alzheimer Disease
- Interventions
- Donepezil Hydrochloride, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 50 Years to 95 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2021
- U.S. locations
- 1
- States / cities
- Mineola, New York
- Conditions
- Alzheimer's Disease
- Interventions
- Donepezil TDS, Aricept
- Drug
- Lead sponsor
- Corium, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Brain Tumor, Brain Cancer, Cns Cancer, Cognitive Dysfunction
- Interventions
- donepezil and questionaires
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer's Disease
- Interventions
- SB-742457 15mg, SB-742457 35mg, Placebo, donepezil 5-10mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 682 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 14
- States / cities
- Litchfield Park, Arizona • Fresno, California • Rancho Mirage, California + 11 more
- Conditions
- Cocaine Use Disorders
- Interventions
- High-dose donepezil, Low-dose donepezil, Selegiline, Placebo
- Drug
- Lead sponsor
- Midwest Biomedical Research
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Autism Spectrum Disorder
- Interventions
- Melatonin and Donepezil, Placebo
- Drug · Other
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Cognition Disorders, Alzheimer Disease
- Interventions
- Donepezil, Ginkgo Biloba Extract
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Multiple Sclerosis
- Interventions
- donepezil, glucose
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years to 56 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Stony Brook, New York